125 related articles for article (PubMed ID: 32727491)
1. Prevalence of antibodies against a cyclic peptide mimicking the FG loop of the human papillomavirus type 16 capsid among Tunisian women.
Hassen E; Bansal D; Ghdira R; Chaieb A; Khairi H; Zakhama A; Remadi S; Hoebeke J; Sultan AA; Chouchane L
J Transl Med; 2020 Jul; 18(1):288. PubMed ID: 32727491
[TBL] [Abstract][Full Text] [Related]
2. Correlation between cervical HPV DNA detection and HPV16 seroreactivity measured with L1-only and L1+L2 viral capsid antigens.
Trevisan A; Candeias JMG; Thomann P; Villa LL; Franco EL; Trottier H; The Ludwig-McGill Study Group
J Med Microbiol; 2020 Jul; 69(7):960-970. PubMed ID: 32510304
[No Abstract] [Full Text] [Related]
3. A virus-like particle enzyme-linked immunosorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16.
Kirnbauer R; Hubbert NL; Wheeler CM; Becker TM; Lowy DR; Schiller JT
J Natl Cancer Inst; 1994 Apr; 86(7):494-9. PubMed ID: 8133532
[TBL] [Abstract][Full Text] [Related]
4. Contribution of Surface-Exposed Loops on the HPV16 Capsid to Antigenic Domains Recognized by Vaccine or Natural Infection Induced Neutralizing Antibodies.
Godi A; Vaghadia S; Cocuzza C; Miller E; Beddows S
Microbiol Spectr; 2022 Jun; 10(3):e0077922. PubMed ID: 35475682
[TBL] [Abstract][Full Text] [Related]
5. Worldwide genetic variations in high-risk human papillomaviruses capsid L1 gene and their impact on vaccine efficiency.
Oumeslakht L; Ababou M; Badaoui B; Qmichou Z
Gene; 2021 May; 782():145533. PubMed ID: 33636291
[TBL] [Abstract][Full Text] [Related]
6. A longitudinal study of human papillomavirus 16 L1, e6, and e7 seropositivity and oral human papillomavirus 16 infection.
Beachler DC; Viscidi R; Sugar EA; Minkoff H; Strickler HD; Cranston RD; Wiley DJ; Jacobson LP; Weber KM; Margolick JB; Reddy S; Gillison ML; D'Souza G
Sex Transm Dis; 2015 Feb; 42(2):93-7. PubMed ID: 25585068
[TBL] [Abstract][Full Text] [Related]
7. [Distribution of serum antibodies against human papillomavirus 16 and 18 among high-risk women to cervical cancer].
Fei M; Li J; Du J; You J; Zhang S; He W; Kang L; Zhao F; Qiao Y; Si Y; Fan X; Chen W
Zhonghua Liu Xing Bing Xue Za Zhi; 2014 May; 35(5):514-8. PubMed ID: 25059358
[TBL] [Abstract][Full Text] [Related]
8. Seroepidemiology of Human Papillomavirus 16 (HPV16) L2 and Generation of L2-Specific Human Chimeric Monoclonal Antibodies.
Wang JW; Jagu S; Wu WH; Viscidi RP; Macgregor-Das A; Fogel JM; Kwak K; Daayana S; Kitchener H; Stern PL; Gravitt PE; Trimble CL; Roden RB
Clin Vaccine Immunol; 2015 Jul; 22(7):806-16. PubMed ID: 25972404
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
10. Neutralization of HPV16, 18, 31, and 58 pseudovirions with antisera induced by immunizing rabbits with synthetic peptides representing segments of the HPV16 minor capsid protein L2 surface region.
Kondo K; Ishii Y; Ochi H; Matsumoto T; Yoshikawa H; Kanda T
Virology; 2007 Feb; 358(2):266-72. PubMed ID: 17010405
[TBL] [Abstract][Full Text] [Related]
11. National experience in the first two years of primary human papillomavirus (HPV) cervical screening in an HPV vaccinated population in Australia: observational study.
Smith MA; Sherrah M; Sultana F; Castle PE; Arbyn M; Gertig D; Caruana M; Wrede CD; Saville M; Canfell K
BMJ; 2022 Mar; 376():e068582. PubMed ID: 35354610
[TBL] [Abstract][Full Text] [Related]
12. A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16 infection.
Monroy-García A; Gómez-Lim MA; Weiss-Steider B; la Rosa GP; Hernández-Montes J; Pérez-Saldaña K; Tapia-Guerrero YS; Toledo-Guzmán ME; Santiago-Osorio E; Sanchez-Peña HI; Mora-García Mde L
Virol J; 2011 Feb; 8():59. PubMed ID: 21306638
[TBL] [Abstract][Full Text] [Related]
13. E2/E6 ratio and L1 immunoreactivity as biomarkers to determine HPV16-positive high-grade squamous intraepithelial lesions (CIN2 and 3) and cervical squamous cell carcinoma.
Choi YJ; Lee A; Kim TJ; Jin HT; Seo YB; Park JS; Lee SJ
J Gynecol Oncol; 2018 May; 29(3):e38. PubMed ID: 29400024
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus type 16 molecular variants in Guarani Indian women from Misiones, Argentina.
Tonon SA; Basiletti J; Badano I; Alonio LV; Villa LL; Teyssie AR; Picconi MA
Int J Infect Dis; 2007 Jan; 11(1):76-81. PubMed ID: 16859947
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of serum antibodies to synthetic peptides to HPV16 epitopes among Indian women with cervical neoplasia.
Sharma BK; Ray A; Murthy NS
Eur J Cancer; 1996 May; 32A(5):872-6. PubMed ID: 9081369
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and age-wise distribution of Human Papillomavirus type 16/18 infections among hospital screened women of a peri-urban area in West Bengal: Impact of socio-demographic factors.
Bhattacharya A; Sen S; Mandal P; Sharma Saha S; Sarkar S; Pathak OP; Biswas L; Roy J; Banerjee R; Roy Chowdhury R; Pal M; Mukherjee A; Sengupta S
Cancer Epidemiol; 2018 Jun; 54():31-37. PubMed ID: 29571035
[TBL] [Abstract][Full Text] [Related]
17. Developments in L2-based human papillomavirus (HPV) vaccines.
Schellenbacher C; Roden RBS; Kirnbauer R
Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616
[TBL] [Abstract][Full Text] [Related]
18. Preparation, Characterization and Diagnostic Valuation of Two Novel Anti-HPV16 E7 Oncoprotein Monoclonal Antibodies.
Hu R; Dong Z; Zhang K; Pan G; Li C; Cui H
Viruses; 2020 Mar; 12(3):. PubMed ID: 32204370
[TBL] [Abstract][Full Text] [Related]
19. Phylogeny and Classification of Human Papillomavirus (HPV)16 and HPV18 Variants Based on E6 and L1 genes in Tunisian Women with Cervical Lesions.
Jendoubi-Ferchichi M; Satouri L; Ghoul F; Malek-Mellouli M; Derbel AM; Makni MK; Reziga H; Baba A; Zili M; Segondy M; Khelifa R
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3361-3366. PubMed ID: 30583341
[TBL] [Abstract][Full Text] [Related]
20. Mucosal IgG and IgA responses to human papillomavirus type 16 capsid proteins in HPV16-infected women without visible pathology.
Rocha-Zavaleta L; Pereira-Suarez AL; Yescas G; Cruz-Mimiaga RM; Garcia-Carranca A; Cruz-Talonia F
Viral Immunol; 2003; 16(2):159-68. PubMed ID: 12828867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
